Tobacco addiction: A treatable chronic disease and the importance of boosting the frequency of quit attempts and the role that medicines innovation can play
Update RequiredTo play the media you will need to either update your browser to a recent version or update your Flash plugin.
Dr Alex Bobak GP and GPSI in Smoking Cessation, Wandsworth Medical Centre, London
Dr Sarah Clarke MB BS, Consultant to GlaxoSmithKline Consumer Healthcare
Abstract
YOU CAN WATCH THIS GREAT PRESENTATION ON YOUTUBE - TO OPEN IT IN A NEW WINDOW CLICK HERE
Dr. Bobak - Tobacco addiction: a treatable chronic disease.
Dr. Bobak discussed:
• The need for a fundamental change, moving away from intermittent intervention to ongoing, evidence based treatment and support
like other chronic diseases.
• Why we should think of and refer to smokers as addicts and make it normal to talk about tobacco addiction as a chronic disease
You can view the presentation on youtube, by clicking Dr Alex Bobak here (opens in a new window)
Dr. Clarke - The importance of boosting the frequency of quit attempts and the role that medicines innovation can play
Smokers may make numerous unsuccessful or partially successful quit attempts before finally managing to become smoke-free. How can we encourage more people to try to quit more often and to use the resources available to them to maximise their chances?
Dr Clarke will look at data comparing how we are doing in the UK compared to abroad and how the introduction of stop smoking products in to the market can stimulate both new and failed quitters to try again. The presentation will conclude with a brief introduction to the new nicotine oral strips from GSK.
Source of funding: GlaxoSmithKline Consumer Healthcare
Declaration of interest: Dr. Bobak has received sponsorship to attend scientific meetings, speaker honorariums and consultancy fees from Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Pfizer.
Dr. Clarke works as a consultant to GlaxoSmithKline Consumer Healthcare.
